Kate Therapeutics’ Post

Happy #WorldOrganoidResearchDay! 🧠🔬 Today, we honor the potential of #organoids—tiny clusters of cells that mimic the structure and function of specific organs. These 3D cell models have opened up new avenues in medicine and scientific research. 📖 In our latest mini-review, we delve into the predictive power of organoids in drug discovery. From performance in recent drug evaluation studies to best practices for optimizing organoid-based models, it’s a must-read. By recapitulating key features of the represented organ, organoids are our window into the intricate world of human biology. Let’s celebrate their impact! 🙌

If you are still wondering how organoids can support your drug discovery research - take a look at this mini review! 👀

🚀 2N Pharma is on the road 🌍 As the conference season kicks off, we are excited to announce our participation in several key events over the next couple of months: LSX Nordic Congress 📆 Oct 8 - Oct 9, 2024 📍Copenhagen, Denmark 17th Drug Discover Strategic Summit  📆 Oct 23 - Oct 24, 2024 📍Munich, Germany Redeye AB´s 7th Annual Event on Drug Development in Neurology and Brain Diseases 📆 Oct 23, 2024 📍Stockholm, Sweden BIO-Europe EBD Group 📆 Nov 4 - Nov 6, 2024 📍Stockholm, Sweden These events offer incredible opportunities to connect, share insights, and explore the latest trends shaping the biotech and pharmaceutical industries. We are looking forward to engaging in discussions and meeting with partners, and investors. Let’s connect! If you are attending any of these conferences and would like to schedule a one-on-one meeting, feel free to reach out. We cannot wait to explore new possibilities together! #Biotech #Pharma #Innovation #Networking #2NPharma #ConferenceSeason #ALS #neuroscience #ResearchofALS #EndALS

Paweł Kozielewicz, Assistant Professor at the Karolinska Institutet, shares his expertise in Molecular Pharmacology of G protein-coupled receptors (GPCRs) in the latest #DrugDiscoveryDialogues series. Discover the significance of class F (Frizzled, FZD) GPCRs in development and signaling, and their implications in various diseases. Learn about the challenges in investigating FZDs and the innovative biophysical techniques developed by Pawel's research team to study conformational changes, ligand/receptor interactions, and signaling in in vitro models. Find out more here: https://lnkd.in/e_f7HhYt #DrugDiscovery #MolecularPharmacology #GPCRs

𝗦𝘆𝗻𝗖𝗥𝗢𝗣𝗮𝘁𝗰𝗵 𝟯𝟴𝟰: 𝗗𝗿𝗶𝘃𝗶𝗻𝗴 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗜𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 ✅🔬👩🔬 SB Drug Discovery specializes in ion channel and receptor drug discovery services, offering customized solutions from cell line and assay development to high-throughput screening and lead optimization. To keep up with the growing demands and rapid progress of their field, SB Drug Discovery employs Nanion's sophisticated electrophysiology platforms. The SyncroPatch 384 exemplifies this, allowing for recordings from up to 384 cells simultaneously, which minimizes compound consumption and manual labor. In partnership with Nanion, SB Drug Discovery stands at the cutting edge of innovative scientific research. They are investigating the lysosomal cation channel TMEM175, recognized as a promising therapeutic target for Parkinson's disease. Their joint research emphasizes the effectiveness and versatility of Nanion's tools, notably the SyncroPatch 384 and SURFE²R 96SE, highlighting the significance of a comprehensive approach to the analysis of complex biological systems. For an in-depth look at SB Drug Discovery’s work, download the case study here: https://ow.ly/MtKM50RjSPO We are proud of our lasting partnership and look forward to more groundbreaking discoveries in the future! 👏 David Dalrymple #IonChannels #DrugDiscoveryServices #Electrophysiology #Innovation #CollaborativeScience #CRO #SyncroPatch384 #SURFE2R #APC

Organoid co-cultures and organ-on-a-chip (OoC) systems are advanced in vitro models that further enhance the physiological relevance of organoids by incorporating a broader array of tissue components compared to conventional organoid cultures. Read this mini review to learn about the Predictive Power of Organoids in Drug Discovery and see key takeaways below: - Although immortalized cell lines and animal models are useful for many applications in drug discovery, they are limited by their reductive and cross-species characteristics, respectively, which affect their ability to predict human in vivo responses with sufficient accuracy. - Organoids are high-fidelity biological models that can recapitulate the cellular structure and function of specific organs, can be expanded and stored for long periods, and are compatible with a wide range of assays, including high-throughput screening. - Organoids have demonstrated predictive power with notable sensitivity and specificity in recent drug evaluation studies. - Incorporating human stem cells or stem cell-derived organoids into complex systems such as co-culture and OoC systems is a powerful way to closely model metabolic, transport, and other physiological cellular characteristics of the tissue of interest, maximizing the predictive value of these systems for drug discovery research.

Scientists at Roche’s Institute of Human Biology and Pharma Research & Early Development have achieved a significant milestone in organoid engineering by creating human models that incorporate tissue-resident immune cells.   Unlike previous models that used blood-derived immune cells, these immuno-organoids offer a more accurate representation of the body’s innate biology.   This pioneering work not only enhances the understanding of gut biology and immune response but also opens new avenues for studying tumor growth and autoimmune diseases. The researchers hope this work will lead them towards being able to accurately model and predict whether or not a drug will work.   This breakthrough represents a crucial step toward Roche’s goal of reducing, refining, and replacing the use of animal models in pharmaceutical research.   Read more from Roche: https://lnkd.in/gHucFemy   Find the published research in Nature Portfolio: https://lnkd.in/eS74ZzBi   #Organoid #RocheScience #pRED #TeamIHB

The 4th Annual AnaBios Translational Research Grant is now open for abstract submissions. The winning scientist will receive $15,000 in tissue samples to propel their translational research project forward. Explore more about the grant and submission guidelines on our website. #TranslationalResearch #DrugDiscovery #HeartResearch #PainResearch #Toxicology

When it comes to drug development, precision is key. 🔑 Inoviv's novel NeuroKey-3™ assay has shown record-breaking precision across target proteomics platforms. Taking away the technical variability makes it easier to detect pharmacological variability, which is essential for data-driven clinical trial insights. Ernestas Sirka, Chief Scientific Officer at Inoviv, describes the significance of the analytical validation in the clip below. To find out more about what this means for neurodegenerative drug discovery and development, view the full webinar on-demand: https://hubs.li/Q02BJYS20 #DrugDiscovery #DrugDevelopment #AlzheimersDisease #BiotechWebinar #Biopharma #Proteomics #Neurodegeneration

We're still accepting abstract submissions for the 4th Annual AnaBios Translational Research Grant. The winning scientist will receive $15,000 in tissue samples to help with their translational research project. The deadline to apply is June 30. Learn more about submission guidelines on our website. #TranslationalResearch #DrugDiscovery #HeartResearch #PainResearch #Toxicology